A carregar...
Endometrial safety of ospemifene: results of the phase 2/3 clinical development program
OBJECTIVE: This study aims to assess the endometrial safety of ospemifene based on phase 2/3 clinical trials of postmenopausal women with up to 52 weeks of exposure to ospemifene 60 mg/day versus placebo. METHODS: Endometrial safety was evaluated in a development program of six randomized, double-bl...
Na minha lista:
| Publicado no: | Menopause |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott-Raven Publishers
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4274342/ https://ncbi.nlm.nih.gov/pubmed/24977459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000000275 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|